NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

DCVax-L is clearly 1st line adjuvant.

On the blood cancers, I do not know the numbers but many/most patients relapse while still in good health. So the second and third line markets can be quite large.

In GBM, nothing really works well second line. So the money is first line (including adjuvant).

[I guess the Hat and Avaston have been shown to "work" if one counts such minor benefit]